Anti-CD19 humanized antibody and immune effector cell targeting cd 19
US11427633B2 · kind B2 · utility
0Cited by
4References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 13, 2017 |
| Grant date | Aug 30, 2022 |
| Priority date | — |
| Expiry date | Dec 13, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are an anti-CD19 humanized antibody prepared from a murine monoclonal antibody, a chimeric antigen receptor containing the humanized antibody, and an immune cell expressing the humanized antibody. Not only does the humanized antibody of the present invention not produce an anti-antibody response (AAR) and a human anti-mouse antibody response (HAMA), but same also has better affinity than a murine antibody, and has excellent activity and safety, thereby providing a new means for treating CD19-expressing tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.